Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib
Clinical trial NCT04790474 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04790474
- Sponsor
- Tel-Aviv Sourasky Medical Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-25
- Primary completion
- 2027-09-01
- Enrollment
- 61
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.